Cargando…
Assessment of integrated specialty pharmacy services as a medication optimization strategy for rifaximin in hepatic encephalopathy patients
Background: Lactulose non-adherence has been identified as a factor for recurrent episodes of hepatic encephalopathy (HE). Treatment guidelines recommend adding rifaximin (Xifaxan(1)) to lactulose for ongoing management after an overt HE recurrence on lactulose alone to reduce the risk of further ep...
Autores principales: | Mac, Elezabeth, Battershell, Alicia, Buaisha, Haitam, Nolan, Kami |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764388/ http://dx.doi.org/10.1080/21556660.2019.1658320 |
Ejemplares similares
-
Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011) -
2507. Sex and race disparities in hepatocellular carcinoma surveillance in patients with chronic hepatitis B: a single center retrospective review
por: Reiche, William, et al.
Publicado: (2023) -
Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016) -
Sex and Race Disparities in Hepatocellular Carcinoma Surveillance in Patients With Chronic Hepatitis B During COVID-19: A Single-Center Retrospective Review
por: Reiche, William S., et al.
Publicado: (2023) -
Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)